These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 9438022)

  • 41. Synthesis and biological activity of novel 1,4-diazepane derivatives as factor Xa inhibitor with potent anticoagulant and antithrombotic activity.
    Koshio H; Hirayama F; Ishihara T; Taniuchi Y; Sato K; Sakai-Moritani Y; Kaku S; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2004 May; 12(9):2179-91. PubMed ID: 15080918
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors.
    Zbinden KG; Obst-Sander U; Hilpert K; Kühne H; Banner DW; Böhm HJ; Stahl M; Ackermann J; Alig L; Weber L; Wessel HP; Riederer MA; Tschopp TB; Lavé T
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5344-52. PubMed ID: 16213138
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phenyltriazolinones as potent factor Xa inhibitors.
    Quan ML; Pinto DJ; Rossi KA; Sheriff S; Alexander RS; Amparo E; Kish K; Knabb RM; Luettgen JM; Morin P; Smallwood A; Woerner FJ; Wexler RR
    Bioorg Med Chem Lett; 2010 Feb; 20(4):1373-7. PubMed ID: 20100660
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1.
    Quan ML; Liauw AY; Ellis CD; Pruitt JR; Carini DJ; Bostrom LL; Huang PP; Harrison K; Knabb RM; Thoolen MJ; Wong PC; Wexler RR
    J Med Chem; 1999 Jul; 42(15):2752-9. PubMed ID: 10425086
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray crystallography, 3D-QSAR, and tailored scoring functions.
    Matter H; Will DW; Nazaré M; Schreuder H; Laux V; Wehner V
    J Med Chem; 2005 May; 48(9):3290-312. PubMed ID: 15857135
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cycloalkanediamine derivatives as novel blood coagulation factor Xa inhibitors.
    Nagata T; Yoshino T; Haginoya N; Yoshikawa K; Isobe Y; Furugohri T; Kanno H
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4683-8. PubMed ID: 17555959
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket.
    Maignan S; Guilloteau JP; Choi-Sledeski YM; Becker MR; Ewing WR; Pauls HW; Spada AP; Mikol V
    J Med Chem; 2003 Feb; 46(5):685-90. PubMed ID: 12593649
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives.
    Koshio H; Hirayama F; Ishihara T; Kaizawa H; Shigenaga T; Taniuchi Y; Sato K; Moritani Y; Iwatsuki Y; Uemura T; Kaku S; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2004 Oct; 12(20):5415-26. PubMed ID: 15388168
    [TBL] [Abstract][Full Text] [Related]  

  • 49. (Z,Z)-2,7-Bis(4-amidinobenzylidene)cycloheptan-1-one: identification of a highly active inhibitor of blood coagulation factor Xa.
    Shaw KJ; Guilford WJ; Dallas JL; Koovakkaat SK; McCarrick MA; Liang A; Light DR; Morrissey MM
    J Med Chem; 1998 Sep; 41(19):3551-6. PubMed ID: 9733479
    [No Abstract]   [Full Text] [Related]  

  • 50. Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex.
    Parlow JJ; Case BL; Dice TA; Fenton RL; Hayes MJ; Jones DE; Neumann WL; Wood RS; Lachance RM; Girard TJ; Nicholson NS; Clare M; Stegeman RA; Stevens AM; Stallings WC; Kurumbail RG; South MS
    J Med Chem; 2003 Sep; 46(19):4050-62. PubMed ID: 12954058
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anthranilamide inhibitors of factor Xa.
    Mendel D; Marquart AL; Joseph S; Waid P; Yee YK; Tebbe AL; Ratz AM; Herron DK; Goodson T; Masters JJ; Franciskovich JB; Tinsley JM; Wiley MR; Weir LC; Kyle JA; Klimkowski VJ; Smith GF; Towner RD; Froelich LL; Buben J; Craft TJ
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4832-6. PubMed ID: 17624775
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors.
    Ye B; Arnaiz DO; Chou YL; Griedel BD; Karanjawala R; Lee W; Morrissey MM; Sacchi KL; Sakata ST; Shaw KJ; Wu SC; Zhao Z; Adler M; Cheeseman S; Dole WP; Ewing J; Fitch R; Lentz D; Liang A; Light D; Morser J; Post J; Rumennik G; Subramanyam B; Sullivan ME; Vergona R; Walters J; Wang YX; White KA; Whitlow M; Kochanny MJ
    J Med Chem; 2007 Jun; 50(13):2967-80. PubMed ID: 17536795
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification and initial structure-activity relationships of a novel class of nonpeptide inhibitors of blood coagulation factor Xa.
    Klein SI; Czekaj M; Gardner CJ; Guertin KR; Cheney DL; Spada AP; Bolton SA; Brown K; Colussi D; Heran CL; Morgan SR; Leadley RJ; Dunwiddie CT; Perrone MH; Chu V
    J Med Chem; 1998 Feb; 41(4):437-50. PubMed ID: 9484495
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The discovery of glycine and related amino acid-based factor Xa inhibitors.
    Kohrt JT; Filipski KJ; Cody WL; Bigge CF; La F; Welch K; Dahring T; Bryant JW; Leonard D; Bolton G; Narasimhan L; Zhang E; Peterson JT; Haarer S; Sahasrabudhe V; Janiczek N; Desiraju S; Hena M; Fiakpui C; Saraswat N; Sharma R; Sun S; Maiti SN; Leadley R; Edmunds JJ
    Bioorg Med Chem; 2006 Jul; 14(13):4379-92. PubMed ID: 16529937
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design, synthesis, and activity of a novel series of factor Xa inhibitors: optimization of arylamidine groups.
    Phillips G; Guilford WJ; Buckman BO; Davey DD; Eagen KA; Koovakkat S; Liang A; McCarrick M; Mohan R; Ng HP; Pinkerton M; Subramanyam B; Ho E; Trinh L; Whitlow M; Wu S; Xu W; Morrissey MM
    J Med Chem; 2002 Jun; 45(12):2484-93. PubMed ID: 12036356
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimization of a coagulation factor VIIa inhibitor found in factor Xa inhibitor library.
    Sagi K; Fujita K; Sugiki M; Takahashi M; Takehana S; Tashiro K; Kayahara T; Yamanashi M; Fukuda Y; Oono S; Okajima A; Iwata S; Shoji M; Sakurai K
    Bioorg Med Chem; 2005 Mar; 13(5):1487-96. PubMed ID: 15698764
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
    Bhongade BA; Gouripur VV; Gadad AK
    Bioorg Med Chem; 2005 Apr; 13(8):2773-82. PubMed ID: 15781388
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design, parallel synthesis, and crystal structures of biphenyl antithrombotics as selective inhibitors of tissue factor FVIIa complex. Part 1: Exploration of S2 pocket pharmacophores.
    Kotian PL; Krishnan R; Rowland S; El-Kattan Y; Saini SK; Upshaw R; Bantia S; Arnold S; Babu YS; Chand P
    Bioorg Med Chem; 2009 Jun; 17(11):3934-58. PubMed ID: 19409795
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Kinetics of factor Xa inhibition by recombinant tick anticoagulant peptide: both active site and exosite interactions are required for a slow- and tight-binding inhibition mechanism.
    Rezaie AR
    Biochemistry; 2004 Mar; 43(12):3368-75. PubMed ID: 15035608
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effective inhibition of experimental metastasis and prolongation of survival in mice by a potent factor Xa-specific synthetic serine protease inhibitor with weak anticoagulant activity.
    Banke IJ; Arlt MJ; Mueller MM; Sperl S; Stemberger A; Stürzebecher J; Amirkhosravi A; Moroder L; Krüger A
    Thromb Haemost; 2005 Nov; 94(5):1084-93. PubMed ID: 16363253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.